Pharmacovigilance Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Pharmacovigilance. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Pharmacovigilance Indian Medical PG Question 1: HIV sentinel surveillance is used for:
- A. Detection of high-risk group
- B. Prevalence of HIV infection
- C. Monitoring trends in HIV infection (Correct Answer)
- D. Monitoring disease trends
Pharmacovigilance Explanation: ***Monitoring trends in HIV infection***
- **HIV sentinel surveillance** is specifically designed to track **HIV prevalence trends** over time in selected sentinel populations (ANC attendees, STD clinic attendees, high-risk groups).
- The primary objective is to monitor **how HIV infection rates change** over time, helping identify emerging epidemics, evaluate intervention programs, and guide public health policy.
- As per **NACO and WHO guidelines**, sentinel surveillance provides repeated cross-sectional prevalence measurements at fixed sites to detect temporal trends in HIV infection.
*Monitoring disease trends*
- This is **too broad and vague** for the specific purpose of HIV sentinel surveillance.
- "Disease trends" could refer to AIDS progression, opportunistic infections, or other disease manifestations, which are **not the focus** of sentinel surveillance.
- Sentinel surveillance specifically tracks **infection (seroprevalence)**, not general disease patterns.
*Prevalence of HIV infection*
- While sentinel surveillance **does measure prevalence**, this is a **method rather than the ultimate purpose**.
- Prevalence measurements are taken repeatedly at different time points specifically to **monitor trends**, making this incomplete as the primary objective.
*Detection of high-risk group*
- Identification of high-risk groups is typically done through **epidemiological studies** and behavioral surveys, not sentinel surveillance.
- Sentinel surveillance may **include** high-risk populations as sentinel sites, but its purpose is to monitor trends **within** these groups, not to detect them.
Pharmacovigilance Indian Medical PG Question 2: Which of the following statements about drug-induced SLE is NOT true?
- A. Female: Male ratio=1:9 (Correct Answer)
- B. CNS involvement not common
- C. Renal involvement not common
- D. Anti-histone antibodies are negative
Pharmacovigilance Explanation: ***Female: Male ratio=1:9***
- Drug-induced lupus erythematosus (DILE) typically has no significant **gender predilection**, unlike idiopathic SLE which has a marked female predominance (9:1 female: male ratio) [1].
- This statement is incorrect because the male:female ratio is closer to 1:1, or even male predominance, making the given ratio of 1:9 (female:male) false.
*Anti-histone antibodies are negative*
- **Anti-histone antibodies** are positive in 95% of patients with drug-induced lupus, making this statement incorrect.
- The presence of anti-histone antibodies is a hallmark diagnostic feature of drug-induced lupus.
*CNS involvement not common*
- **Central nervous system (CNS) manifestations** are indeed uncommon in drug-induced lupus erythematosus.
- This statement accurately reflects a key differentiating feature from idiopathic systemic lupus erythematosus (SLE), where CNS involvement can be significant [1].
*Renal involvement not common*
- **Renal involvement** is rare in drug-induced lupus erythematosus.
- This statement is true and helps distinguish drug-induced lupus from idiopathic SLE, where renal disease (lupus nephritis) is a frequent and serious complication [1].
Pharmacovigilance Indian Medical PG Question 3: A patient on warfarin has a high INR. Which drug likely caused this?
- A. Amiodarone (Correct Answer)
- B. Phenytoin
- C. Carbamazepine
- D. Rifampicin
Pharmacovigilance Explanation: ***Amiodarone***
- Amiodarone is a well-known inhibitor of **CYP2C9**, the primary enzyme responsible for the metabolism of **S-warfarin**, the more potent enantiomer of warfarin.
- Inhibition of warfarin metabolism leads to increased warfarin levels, thereby enhancing its anticoagulant effect and causing a **higher INR**.
*Phenytoin*
- Phenytoin is an **enzyme inducer**, primarily of **CYP2C9** and **CYP3A4**.
- Its interaction with warfarin typically leads to **decreased warfarin levels** and a **lower INR**, reducing the anticoagulant effect.
*Carbamazepine*
- Carbamazepine is a potent **enzyme inducer**, particularly of **CYP3A4** and **CYP2C9**.
- Like phenytoin, it generally leads to **increased warfarin metabolism** and a **reduced INR**, thereby decreasing its anticoagulant efficacy.
*Rifampicin*
- Rifampicin is a strong **inducer of hepatic cytochrome P450 enzymes**, especially **CYP3A4** and **CYP2C9**.
- Its co-administration with warfarin significantly **increases warfarin metabolism**, resulting in **lower warfarin concentrations** and a **decreased INR**.
Pharmacovigilance Indian Medical PG Question 4: Therapeutic drug monitoring is done for:
- A. Aspirin
- B. Heparin
- C. Phenytoin (Correct Answer)
- D. Metformin
Pharmacovigilance Explanation: ***Phenytoin***
- **Phenytoin** has a **narrow therapeutic window**, meaning the difference between an effective and a toxic dose is small, necessitating close monitoring.
- Its **variable absorption** and **nonlinear pharmacokinetics** (saturable metabolism) make individual dosing adjustments critical to maintain therapeutic levels and avoid toxicity.
*Aspirin*
- **Aspirin** is generally not monitored via plasma levels for its analgesic or antiplatelet effects, as its therapeutic effects are often observed at doses where plasma monitoring is not practical or necessary.
- Its primary therapeutic use as an **antiplatelet agent** is evaluated by clinical outcomes rather than drug concentration.
*Heparin*
- **Heparin** is monitored using coagulation tests like **aPTT (activated partial thromboplastin time)** or anti-Xa levels to assess its anticoagulant effect, not direct drug concentration.
- Therapeutic drug monitoring for heparin focuses on its **pharmacodynamic effects** on the clotting cascade rather than its absolute plasma concentration.
*Metformin*
- **Metformin** has a relatively **wide therapeutic index** and its efficacy is primarily measured by reductions in blood glucose and HbA1c, not by plasma drug concentrations.
- It is excreted largely unchanged by the kidneys, and dose adjustments are typically made based on **renal function** and glycemic control.
Pharmacovigilance Indian Medical PG Question 5: Which of the following diseases is primarily monitored under the Integrated Disease Surveillance Program (IDSP)?
- A. Tuberculosis
- B. HIV
- C. Malaria (Correct Answer)
- D. Diabetes
Pharmacovigilance Explanation: ***Malaria***
- Malaria is a significant public health concern with high incidence and mortality, making its surveillance crucial for **disease control and elimination efforts**.
- The IDSP aims for early detection and rapid response to **outbreaks of communicable diseases**, including vector-borne diseases like malaria.
*Tuberculosis*
- While a major public health issue, **tuberculosis (TB)** is primarily monitored under the **National Tuberculosis Elimination Programme (NTEP)**, which has a dedicated and extensive surveillance system.
- The NTEP focuses on active case finding, treatment, and prevention of TB through a specific, robust framework separate from the IDSP's general surveillance.
*HIV*
- **HIV/AIDS** surveillance is conducted under the **National AIDS Control Organisation (NACO)**, which has a specialized program for monitoring prevalence, incidence, and risk behaviors.
- NACO's surveillance includes sentinel surveillance among specific populations and programmatic data collection, distinct from the IDSP's generalized infectious disease monitoring.
*Diabetes*
- **Diabetes** is a **non-communicable disease** and is not primarily monitored under the IDSP, which focuses on infectious disease outbreaks.
- Surveillance for non-communicable diseases like diabetes typically falls under programs dedicated to non-communicable disease prevention and control, focusing on prevalence and risk factors.
Pharmacovigilance Indian Medical PG Question 6: According to Hill's criteria, which of the following is NOT a criterion for establishing causality in noncommunicable diseases?
- A. Strength of association
- B. Absence of temporal sequence (Correct Answer)
- C. Dose response relationship
- D. Specificity of association
Pharmacovigilance Explanation: ***Absence of temporal sequence***
- A crucial criterion for establishing causality is the **presence of a temporal sequence**, meaning the exposure must precede the outcome.
- The **absence of a temporal sequence** would argue directly against causality, as the cause cannot come after the effect.
*Strength of association*
- This criterion suggests that a **stronger statistical association** between an exposure and an outcome makes a causal relationship more likely.
- A large **relative risk** or **odds ratio** indicates a strong association.
*Dose response relationship*
- This criterion implies that as the **amount or duration of exposure increases**, the **risk or severity of the outcome also increases**.
- This **dose-response gradient** strengthens the argument for a causal link.
*Specificity of association*
- This criterion suggests that a single exposure leads to a **specific effect**, and not a wide range of unrelated effects.
- While helpful, **lack of specificity does not rule out causality**, as many exposures can have multiple effects.
Pharmacovigilance Indian Medical PG Question 7: A district shows API of 4.2, ABER 11%, and SPR 3.1%. What is the malaria surveillance status?
- A. Poor surveillance
- B. Cannot be determined
- C. Adequate surveillance (Correct Answer)
- D. Optimal surveillance
Pharmacovigilance Explanation: ***Adequate surveillance***
- An **ABER of 11%** meets the WHO minimum threshold of **≥10%** for adequate malaria surveillance, indicating that blood examination is occurring at an acceptable level.
- An **API of 4.2** per 1000 population indicates moderate malaria transmission with reasonable case detection.
- An **SPR of 3.1%** is within the acceptable range (1-5%), suggesting balanced testing practices—not excessively high (which would indicate poor case detection) or extremely low (though lower would be better).
- Together, these metrics indicate a **functioning surveillance system** that meets basic adequacy criteria but has room for optimization.
*Poor surveillance*
- This would be characterized by **ABER <10%** (indicating inadequate blood examination coverage), very **high SPR >10%** (suggesting only highly symptomatic cases are tested), or extremely low reporting rates.
- The given values (API 4.2, ABER 11%, SPR 3.1%) do not align with poor surveillance indicators.
*Cannot be determined*
- The three epidemiological indicators provided (API, ABER, SPR) are **standard WHO metrics** specifically designed to assess malaria surveillance effectiveness.
- These metrics provide **sufficient information** to make a determination about surveillance status.
*Optimal surveillance*
- Optimal surveillance would require **ABER ≥20-50%** (much higher blood examination coverage), **SPR <2%** (indicating highly sensitive early case detection), and comprehensive reporting systems.
- While the current ABER of 11% is adequate, it is just above the minimum threshold and would need substantial improvement to reach optimal levels.
Pharmacovigilance Indian Medical PG Question 8: Cisapride was withdrawn from the market due to?
- A. QT Prolongation (Correct Answer)
- B. Hepatotoxicity
- C. Nephrotoxicity
- D. PR interval prolongation
Pharmacovigilance Explanation: ***QT Prolongation***
- Cisapride was withdrawn from the market primarily due to its association with **dose-dependent QT interval prolongation**, which increased the risk of serious ventricular arrhythmias.
- This **QT prolongation** could lead to potentially fatal **Torsades de Pointes**, a polymorphic ventricular tachycardia.
*PR interval prolongation*
- While some medications can affect the PR interval, **cisapride's primary cardiac concern** was specifically related to the QT interval, not the PR interval.
- PR interval changes generally indicate issues with **AV nodal conduction**, a different mechanism than that affected by cisapride.
*Hepatotoxicity*
- Although drug-induced liver injury is a known adverse effect for many medications, **hepatotoxicity was not the primary reason** for cisapride's withdrawal.
- The most significant and life-threatening adverse effect was its impact on cardiac repolarization.
*Nephrotoxicity*
- **Nephrotoxicity (kidney damage)** was not identified as a major or significant adverse effect associated with cisapride that led to its market withdrawal.
- The drug's safety profile concerns were focused on its cardiovascular effects.
Pharmacovigilance Indian Medical PG Question 9: Permission from DCGI [Drug controller general, India] is needed before which phase of drug trial?
- A. Phase 1
- B. Phase 2
- C. Phase 3 (Correct Answer)
- D. Phase 4
Pharmacovigilance Explanation: ***Phase 3***
- Permission from the **DCGI (Drug Controller General of India)** is mandatory before initiating **Phase 3** clinical trials as per **Schedule Y** of the Drugs and Cosmetics Rules.
- Phase 3 trials involve **large-scale studies in Indian patients** to establish efficacy and safety in the target population, requiring explicit regulatory approval.
- This is the critical regulatory checkpoint where DCGI evaluates the Phase 1 and 2 data before allowing widespread testing in Indian subjects.
*Phase 1*
- Phase 1 trials can be conducted after approval from the **Institutional Ethics Committee (IEC)** without requiring prior DCGI permission.
- These trials in healthy volunteers focus on safety, pharmacokinetics, and dose-ranging studies.
- DCGI is informed but explicit permission is not mandatory at this stage.
*Phase 2*
- Phase 2 trials also proceed with **IEC approval** and do not require prior DCGI permission.
- These trials evaluate therapeutic efficacy and dose determination in a limited number of patients.
- Results from Phase 2 are submitted to DCGI when seeking Phase 3 approval.
*Phase 4*
- Phase 4 trials are **post-marketing surveillance** studies conducted after drug approval.
- These are conducted under the Post-Marketing Surveillance (PMS) framework.
- While regulatory oversight exists, these are not pre-market trials requiring permission to initiate.
Pharmacovigilance Indian Medical PG Question 10: The following malformation in a baby due to drug intake by mother is classified as \qquad ADR?
- A. Type A
- B. Type D (Correct Answer)
- C. Type E
- D. Type F
Pharmacovigilance Explanation: ***Type D***
- **Type D** ADRs are **delayed effects** that include **teratogenicity** and **carcinogenicity**, occurring after prolonged exposure or during critical developmental periods.
- The image shows **phocomelia** (severe limb malformation), a classic example of drug-induced teratogenicity (e.g., **thalidomide**), which is classified as a Type D ADR.
*Type A*
- **Type A** ADRs are **augmented** reactions that are predictable, dose-dependent pharmacological effects of drugs.
- Examples include **bleeding** with anticoagulants or **hypotension** with antihypertensives, not congenital malformations.
*Type E*
- **Type E** ADRs are **end-of-use** effects or **withdrawal symptoms** that occur when a drug is discontinued.
- These reactions (like **opioid withdrawal**) are unrelated to developmental malformations from in-utero drug exposure.
*Type F*
- **Type F** is not a recognized category in standard ADR classification systems, which typically include only Types A through E.
- The established classification covers predictable, unpredictable, chronic, delayed, and end-of-use effects without requiring a Type F category.
More Pharmacovigilance Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
